CMN-005
Clinical experience with CMN-005
Allogeneic Phase 1/2a CARCIK-CD19 (CMN-005) dose escalation Clinical Trial***
- IST trial conducted at 2 sites in Italy
- Adult and pediatric patients with B-cell precursor ALL who are either chemo-refractory or relapsed after allogeneic HSCT
- 4 pediatric/17 adult patients treated
- All patients progressing at time of enrollment
- Single infusion after lymphodepletion
- N=27 evaluable patients
Interim Results
- Phase 1/2a dose escalation (Final data presented at ASH 2022)
- 27 evaluable patients (n=21 at 2 highest dose levels)
- 4 pediatric; 23 adults
- Little to no toxicity observed
- 30% of patients alive at ~3 years of follow-up
***J Clin Invest. (2020) 130(11):6021
CR rate 28 days post-infusion at 2 highest doses N=12
Of CRs minimal residual disease negative
Serious adverse events
Dose limiting toxicities
GVHD, Neurotoxicity
